1. Home
  2. >>Learning

CPD Module - Fexofenadine

 
• By C+D Community and C+D Clinical Team

Allergy insights, Histallay Allergy Room

sponsored
cpc module

What you need to know about Histallay

This content is produced in partnership with Histallay

On December 22, 2020 the Medicines Healthcare and Regulatory Authority (MHRA) published a public assessment report reclassifying fexofenadine 120mg tablets from a prescription only medicine (POM) to general sales list (GSL). Fexofenadine is a non-sedating antihistamine, used to relieve symptoms of allergy such as hayfever, blocked nose and itchy or watery eyes.

Complete this CPD on the C+D Community

https://community.chemistanddruggist.co.uk/posts/cpd-module-fexofenadine?room_id=4400

Sign in or register for free

Latest from Learning

Oral health: Dental Caries

 
• By C+D Community and C+D Clinical Team
 • comment

Oral diseases currently affect 3.6 billion of the world’s population. Find out more in this free video CPD in partnership with Primal Pictures.

What is postmenopausal Vaginal Atrophy (VA)

 
• By C+D Community and C+D Clinical Team
 • comment

Women's health, Welcome to Your Gina Training Room

Evana® and Heavy Menstrual Bleeding (HMB)

 
• By C+D Community and C+D Clinical Team
 • comment

Women's health, Evana® Menstrual Health Room

More from News

exclusive

CPE: Almost half of £645m recovery plan funds unspent

 
• By Kate Bowie
 • comment0

The pharmacy negotiator estimates some £296m of remaining primary care recovery plan funding “will have been used by NHS England (NHSE) in other ways”, C+D has learned.

breaking news

IN FULL: Number of pharmacies drops below 10,000 in 20-year first

 
• By Kate Bowie
 • comment3

Only 9,999 bricks-and-mortar pharmacies remained in England at the end of March, NHS Business Services Authority (NHSBSA) data has revealed.